Yvonne Greenstreet - 03 Aug 2022 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: /s/ Mary Beth DeLena, Attorney-in-Fact For: Yvonne Greenstreet
Issuer symbol
ALNY
Transactions as of
03 Aug 2022
Net transactions value
-$1,150,439
Form type
4
Filing time
05 Aug 2022, 16:13:32 UTC
Previous filing
08 Jun 2022
Next filing
01 Mar 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +5,083 +37% $0.000000 18,985 03 Aug 2022 Direct F1
transaction ALNY Common Stock Award $0 +4,153 +22% $0.000000 23,138 03 Aug 2022 Direct F2
transaction ALNY Common Stock Award $0 +3,859 +17% $0.000000 26,997 03 Aug 2022 Direct F3
transaction ALNY Common Stock Tax liability $1,030,966 -5,433 -20% $189.76 21,564 04 Aug 2022 Direct F4
transaction ALNY Common Stock Tax liability $40,917 -195 -0.9% $209.83 21,369 04 Aug 2022 Direct F4
transaction ALNY Common Stock Tax liability $40,711 -194 -0.91% $209.85 21,175 04 Aug 2022 Direct F4
transaction ALNY Common Stock Tax liability $37,845 -180 -0.85% $210.25 20,995 04 Aug 2022 Direct F4
holding ALNY Common Stock 407 03 Aug 2022 by Managed Account F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022.
F2 On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022.
F3 On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022.
F4 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F5 Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.